{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q3 FY26)",
      "prediction": "BEAT",
      "answer": "pred ~$3.20 vs. cons $3.15",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FXN Revenue Growth (Q3 FY26)",
      "prediction": "BEAT",
      "answer": "pred ~2.9% vs. cons 2.6%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted Operating Margin (Q3 FY26)",
      "prediction": "IN-LINE",
      "answer": "pred ~24.6% vs. cons 24.4%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$12.68-$12.80 (mid ~$12.74) vs. cons $12.62 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Revenue growth (FXN) guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~2.5%-3.0% vs. cons 2.6% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Adjusted Operating Margin guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~25.0% vs. cons 25.0% (FY2026, inclusive of tariffs)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -1.2,
  "day5_path": "FADE",
  "day5_rationale": "Stock has already rallied ~12% in the two weeks into the print (from ~$153 to ~$170.7) on UBS/Barclays target hikes, front-running a likely beat-and-modest-raise, so most good news is priced. Last quarter's pattern (Q2 FY26, reported ~May 7) showed exactly this dynamic: a sharp +~6% day-1 pop on a clean beat-and-raise fully reversed within 5 trading days even as the S&P rose, as the market shifted focus to persistent Alaris/vaccine/China headwinds, tariff-driven margin drag, and the unresolved El Paso/ChloraPrep reserve overhang that caps the size of any raise. With FY26 guidance already raised twice and the stock trading near/above the ~$175 average sell-side target, a merely in-line-to-modest-beat quarter plus an incremental (not dramatic) guidance bump is likely to see initial enthusiasm fade as investors lock in gains from the pre-print run and re-focus on FY27 Alaris headwind widening to 200bps.",
  "day5_confidence": "MEDIUM"
}